These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 20065644)

  • 1. Production of therapeutic antibodies with controlled fucosylation.
    Yamane-Ohnuki N; Satoh M
    MAbs; 2009; 1(3):230-6. PubMed ID: 20065644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.
    Satoh M; Iida S; Shitara K
    Expert Opin Biol Ther; 2006 Nov; 6(11):1161-73. PubMed ID: 17049014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC.
    Imai-Nishiya H; Mori K; Inoue M; Wakitani M; Iida S; Shitara K; Satoh M
    BMC Biotechnol; 2007 Nov; 7():84. PubMed ID: 18047682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.
    Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S
    Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
    Kanda Y; Imai-Nishiya H; Kuni-Kamochi R; Mori K; Inoue M; Kitajima-Miyama K; Okazaki A; Iida S; Shitara K; Satoh M
    J Biotechnol; 2007 Jun; 130(3):300-10. PubMed ID: 17559959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody therapeutics: isotype and glycoform selection.
    Jefferis R
    Expert Opin Biol Ther; 2007 Sep; 7(9):1401-13. PubMed ID: 17727329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of fucosylation inhibitors for production of afucosylated antibody.
    Xu P; Ou YC; Smith M; Paulson J; Schmidt MA; Kandari L; Parsons R; Khetan A
    Biotechnol Prog; 2024; 40(3):e3438. PubMed ID: 38415431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
    Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
    Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity.
    Olivier S; Jacoby M; Brillon C; Bouletreau S; Mollet T; Nerriere O; Angel A; Danet S; Souttou B; Guehenneux F; Gauthier L; Berthomé M; Vié H; Beltraminelli N; Mehtali M
    MAbs; 2010; 2(4):405-15. PubMed ID: 20562528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.
    von Horsten HH; Ogorek C; Blanchard V; Demmler C; Giese C; Winkler K; Kaup M; Berger M; Jordan I; Sandig V
    Glycobiology; 2010 Dec; 20(12):1607-18. PubMed ID: 20639190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and biological activities of anti-HER2 monoclonal antibodies with fully core-fucosylated homogeneous bi-antennary complex-type glycans.
    Tsukimura W; Kurogochi M; Mori M; Osumi K; Matsuda A; Takegawa K; Furukawa K; Shirai T
    Biosci Biotechnol Biochem; 2017 Dec; 81(12):2353-2359. PubMed ID: 29090617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
    Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
    BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies.
    Freimoser-Grundschober A; Rueger P; Fingas F; Sondermann P; Herter S; Schlothauer T; Umana P; Neumann C
    J Chromatogr A; 2020 Jan; 1610():460554. PubMed ID: 31597603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
    PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies.
    Gilormini PA; Thota VN; Fers-Lidou A; Ashmus RA; Nodwell M; Brockerman J; Kuo CW; Wang Y; Gray TE; Nitin ; McDonagh AW; Guu SY; Ertunc N; Yeo D; Zandberg WF; Khoo KH; Britton R; Vocadlo DJ
    Proc Natl Acad Sci U S A; 2024 Jul; 121(27):e2314026121. PubMed ID: 38917011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
    Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative core fucosylation analysis of some major therapeutic antibody N-glycans by direct infusion ESI-MS and CE-LIF detection.
    Wang Y; Santos M; Guttman A
    J Sep Sci; 2013 Sep; 36(17):2862-7. PubMed ID: 23801428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.